Effect of hepatic and renal dysfunction on disposition of bupropion in rats
- PMID: 3149241
- DOI: 10.1007/BF03189933
Effect of hepatic and renal dysfunction on disposition of bupropion in rats
Abstract
Disposition of bupropion after oral administration was investigated in carbon tetrachloride (CCl4) and gentamicin treated rats. Bupropion exhibits extensive first-pass effect and is mainly cleared by hepatic route. In rats with hepatic damage, maximum plasma concentration (Cmax) was approximately 3 times higher and area under the plasma concentration-time curve up to 6 h (AUC 0-6) and AUC 0-infinity increased on an average 4 and 5 times respectively compared to the control. The half-life was doubled with hepatic dysfunction. These findings suggest that hepatic impairment in rats causes a decrease in first pass effect as well as an increase in the half-life of the drug. Rats with renal impairment, exhibited a significant increase in Cmax, AUC 0-6 and AUC 0-infinity of bupropion approximately 3-fold as compared to the control, no change in half life of the drug was observed. This indicates that rats with renal impairment show less efficient first-pass effect which may lead to increase in systemic bioavailability. The time to peak observed in all treated animals was not significantly different from the control. The percentage of bound bupropion did not differ either in CCl4 or gentamicin treated plasma as compared to the control.
Similar articles
-
The effect of H2-antagonists on the absorption of bupropion in rats.Res Commun Chem Pathol Pharmacol. 1988 Feb;59(2):279-82. Res Commun Chem Pathol Pharmacol. 1988. PMID: 2895943
-
Phenytoin-bupropion interaction: effect on plasma phenytoin concentration in the rat.J Pharm Pharmacol. 1990 Nov;42(11):799-801. doi: 10.1111/j.2042-7158.1990.tb07025.x. J Pharm Pharmacol. 1990. PMID: 1982306
-
Therapeutic drug monitoring of bupropion.Am J Psychiatry. 1990 Dec;147(12):1690-1. doi: 10.1176/ajp.147.12.1690. Am J Psychiatry. 1990. PMID: 2123082 No abstract available.
-
Clinical pharmacokinetics of bupropion: a review.J Clin Psychiatry. 1983 May;44(5 Pt 2):82-4. J Clin Psychiatry. 1983. PMID: 6406470 Review.
-
Clinical pharmacokinetics of mycophenolate mofetil.Clin Pharmacokinet. 1998 Jun;34(6):429-55. doi: 10.2165/00003088-199834060-00002. Clin Pharmacokinet. 1998. PMID: 9646007 Review.
Cited by
-
Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites.Br J Clin Pharmacol. 2007 Aug;64(2):165-73. doi: 10.1111/j.1365-2125.2007.02866.x. Epub 2007 Mar 1. Br J Clin Pharmacol. 2007. PMID: 17335546 Free PMC article.
-
Human and rat microsomal metabolites of N-tert-butoxycarbonylmethamphetamine and its urinary metabolites in rat.Forensic Toxicol. 2022 Jan;40(1):75-87. doi: 10.1007/s11419-021-00595-6. Epub 2021 Aug 24. Forensic Toxicol. 2022. PMID: 36454489 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Medical